Gastroesophageal Cancer
Gastrointestinal Cancer

Perioperative Therapy With FLOT vs ECF/ECX in Locally Advanced Gastric Adenocarcinoma

In the German phase II/III FLOT4 trial reported in The Lancet, Al-Batran et al found that perioperative therapy with the docetaxel-based triplet FLOT...

Head and Neck Cancer
Pain Management

Doxepin or Diphenhydramine/Lidocaine/Antacid Mouthwash for Radiotherapy-Related Oral Mucositis Pain

In the phase III Alliance A221304 trial reported in JAMA, Sio et al found that doxepin mouthwash and diphenhydramine/lidocaine/antacid mouthwash...

Lung Cancer

FDA Approves Atezolizumab for Extensive-Stage Small Cell Lung Cancer

On March 18, 2019, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with carboplatin and etoposide...

Multiple Myeloma

FDA Warning: Investigational Use of Venetoclax in Multiple Myeloma

On March 21, 2019, the U.S. Food and Drug Administration (FDA) posted a safety statement on the investigational use of venetoclax in multiple myeloma...

Colorectal Cancer

Dana-Farber Launches Young-Onset Colorectal Cancer Center

Dana-Farber/Brigham and Women’s Cancer Center recently announced the launch of the Young-Onset Colorectal Cancer Center in Boston...


More Top Stories


Jedd D. Wolchok, MD, PhD, on The Future of Immunotherapy: Keynote Lecture

Hematologic Malignancies
Multiple Myeloma

FDA Warning: Investigational Use of Venetoclax in Multiple Myeloma

On March 21, 2019, the U.S. Food and Drug Administration (FDA) posted a safety statement on the investigational use of venetoclax in multiple myeloma. The statement alerts health-care professionals and patients about the suspension of the BELLINI trial ( identifier NCT02755597)...


Low-Dose Tamoxifen vs Placebo in Preventing Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia

In an Italian phase III study reported in the Journal of Clinical Oncology, DeCensi et al found that tamoxifen at 5 mg/d vs placebo for 3 years reduced the risk of recurrence of breast intraepithelial neoplasia and was associated with limited toxicity. As noted by the investigators,...

Kidney Cancer

Rana R. McKay, MD, on Renal Cell Carcinoma: Results From a Trial on Atezolizumab and Bevacizumab

Kidney Cancer

Nivolumab/Ipilimumab in Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

NIVOLUMAB PLUS low-dose ipilimumab continued to demonstrate strong responses as well as a survival benefit with a median of 32.4 months of follow-up as front-line treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma, according to an update of the phase II CheckMate...

ASCO Seeks Applicants for Research Grants to Use Data From CancerLinQ Discovery

ASCO recently announced that it is seeking applications for research grants for projects that use data from CancerLinQ Discovery®—an offering of ASCO’s CancerLinQ® initiative—as a source. CancerLinQ Discovery provides curated sets of deidentified data from patients with cancer to academic...

SUNSHINE Trial: High-Dose Vitamin D May Benefit Patients With Metastatic Colorectal Cancer

Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by delaying progression of the disease. These findings were published by Ng et al in JAMA. Initial trial findings were reported at the 2017...

Solid Tumors

Stefanie C. Fischer, MD, on Nonseminoma: Outcomes After Adjuvant Bleomycin/Etoposide/Cisplatin

Prostate Cancer

SBRT vs Conventionally Fractionated, or Moderately Hypofractionated External-Beam Radiotherapy, for Localized Prostate Cancer

TREATMENT WITH stereotactic body radiation therapy (SBRT) results in a similar safety profile to conventionally fractionated, or moderately hypofractionated external-beam radiotherapy, in men with low- or intermediate- risk prostate cancer, according to preliminary results of the Prostate...


Colonoscopy Polyp Detection Rates and Endoscopist Characteristics

Previous research has suggested that specific factors about the doctor performing colonoscopy—for example, a gastroenterologist vs a surgeon, female vs male—were associated with different rates of detection of precancerous polyps. However, a Cleveland Clinic–led research team...